MeSH term
Frequency | Condition_Probility | Adult | 26 | 0.0 |
Comparative Study | 21 | 0.0 |
Humans | 172 | 0.0 |
Research Support, Non-U.S. Gov't | 111 | 0.0 |
Animals | 127 | 0.0 |
Base Sequence | 26 | 0.0 |
Disease Models, Animal | 10 | 0.0 |
Female | 36 | 0.0 |
Genotype | 10 | 0.0 |
Male | 40 | 0.0 |
Mice | 47 | 0.0 |
Middle Aged | 25 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Receptor, Ciliary Neurotrophic Factor/genetics | 4 | 66.0 |
Receptors, Interleukin-6/genetics | 3 | 50.0 |
Receptors, Nerve Growth Factor/*genetics | 2 | 6.0 |
Ciliary Neurotrophic Factor/*genetics | 6 | 75.0 |
Gene Frequency | 2 | 0.0 |
*Mutation | 3 | 0.0 |
Clinical Trials | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
Biological Transport, Active | 2 | 1.0 |
Nerve Growth Factors/*metabolism | 9 | 11.0 |
Protein Binding | 11 | 0.0 |
Receptors, Nerve Growth Factor/*metabolism | 2 | 4.0 |
Signal Transduction | 18 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Aged | 20 | 0.0 |
Blotting, Western | 3 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Nerve Tissue Proteins/*metabolism | 7 | 2.0 |
Child | 3 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Infant | 2 | 0.0 |
Interleukin-6/*genetics | 3 | 4.0 |
Nerve Tissue Proteins/*genetics | 10 | 1.0 |
RNA, Messenger/genetics | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Receptors, Cytokine/genetics | 3 | 9.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Receptors, Dopamine D2/genetics | 2 | 4.0 |
Schizophrenia/*genetics | 5 | 2.0 |
Ciliary Neurotrophic Factor/*pharmacology | 4 | 80.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Trans-Activators/metabolism | 4 | 0.0 |
Cell Line | 20 | 0.0 |
Ciliary Neurotrophic Factor/*physiology | 2 | 66.0 |
DNA Primers | 5 | 0.0 |
Vasoactive Intestinal Peptide/*genetics | 5 | 26.0 |
Cell Transplantation | 2 | 2.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Alleles | 6 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Biological Assay | 5 | 1.0 |
Cell Survival | 5 | 0.0 |
Cells, Cultured | 30 | 0.0 |
Chick Embryo | 19 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 9 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Neurons/metabolism | 4 | 1.0 |
Open Reading Frames | 2 | 0.0 |
Time Factors | 11 | 0.0 |
Child, Preschool | 2 | 0.0 |
English Abstract | 6 | 0.0 |
Rats | 49 | 0.0 |
Rats, Wistar | 4 | 0.0 |
Ciliary Neurotrophic Factor/genetics | 2 | 100.0 |
Cytokines/*genetics | 2 | 1.0 |
Molecular Sequence Data | 32 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Reference Values | 4 | 0.0 |
Binding Sites | 9 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Transfection | 10 | 0.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Ligands | 3 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Mutation | 5 | 0.0 |
Phenotype | 3 | 0.0 |
Receptors, Cytokine/genetics/*physiology | 2 | 22.0 |
Brain-Derived Neurotrophic Factor/*pharmacology | 2 | 4.0 |
Fibroblast Growth Factor 2/*pharmacology | 2 | 1.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Injections | 3 | 2.0 |
Organ Culture Techniques | 4 | 1.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Brain-Derived Neurotrophic Factor/pharmacology | 6 | 12.0 |
Cell Survival/drug effects | 15 | 1.0 |
Ciliary Neurotrophic Factor/pharmacology | 6 | 60.0 |
Drug Interactions | 2 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 5 | 2.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Nerve Growth Factors/*pharmacology | 18 | 14.0 |
Nerve Tissue Proteins/pharmacology | 11 | 26.0 |
Retina/pathology | 2 | 5.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Cell Count/drug effects | 3 | 4.0 |
*Interleukin-6 | 21 | 5.0 |
Nerve Growth Factor/pharmacology | 2 | 6.0 |
Neurons/*cytology | 2 | 3.0 |
Ciliary Neurotrophic Factor/*genetics/*pharmacology | 2 | 100.0 |
Nerve Growth Factors/*physiology | 5 | 11.0 |
Neuroblastoma | 6 | 3.0 |
Neurotrophin 3/pharmacology | 2 | 28.0 |
Phosphorylation | 5 | 0.0 |
Recombinant Proteins/pharmacology | 17 | 0.0 |
Tumor Cells, Cultured | 19 | 0.0 |
Case-Control Studies | 6 | 0.0 |
Gene Expression | 8 | 0.0 |
Motor Neurons/pathology | 2 | 6.0 |
Growth Inhibitors/pharmacology | 4 | 2.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Lymphokines/pharmacology | 4 | 2.0 |
Models, Neurological | 2 | 1.0 |
Nerve Degeneration | 3 | 4.0 |
Nerve Growth Factors/*pharmacology/physiology | 2 | 50.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Central Nervous System/physiology | 2 | 15.0 |
Interleukin-6/*physiology | 5 | 6.0 |
Neurons/*physiology | 4 | 2.0 |
Protein Conformation | 4 | 0.0 |
Amino Acid Sequence | 18 | 0.0 |
Antigens, CD/*metabolism | 3 | 0.0 |
Cell Division | 5 | 0.0 |
*Growth Inhibitors | 6 | 10.0 |
Interleukin-6/metabolism | 2 | 0.0 |
*Lymphokines | 6 | 13.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Models, Molecular | 5 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Receptors, Cytokine/metabolism | 3 | 3.0 |
Analysis of Variance | 5 | 0.0 |
Ciliary Neurotrophic Factor | 94 | 77.0 |
Nerve Tissue Proteins/*pharmacology | 23 | 25.0 |
Rats, Inbred F344 | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Cats | 2 | 0.0 |
Cell Survival/drug effects/physiology | 3 | 3.0 |
Growth Inhibitors/*blood | 3 | 15.0 |
Interleukin-6/*blood | 4 | 1.0 |
Lymphokines/*blood | 3 | 1.0 |
Nerve Tissue Proteins/blood | 4 | 44.0 |
Peptides/blood | 2 | 5.0 |
Receptors, Interleukin-6/*blood | 3 | 23.0 |
Blotting, Northern | 4 | 0.0 |
Gene Expression/*drug effects | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Nerve Growth Factors/pharmacology | 10 | 12.0 |
Rats, Sprague-Dawley | 13 | 0.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Kinetics | 9 | 0.0 |
Receptors, Nerve Growth Factor/metabolism | 3 | 8.0 |
Cell Division/physiology | 3 | 0.0 |
Disease Progression | 3 | 0.0 |
Cytokines/pharmacology | 3 | 0.0 |
Growth Inhibitors/*pharmacology | 5 | 2.0 |
Lymphokines/*pharmacology | 5 | 1.0 |
Rats, Inbred Strains | 4 | 0.0 |
Recombinant Proteins | 2 | 0.0 |
Adolescent | 4 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Cytokines/*pharmacology | 6 | 1.0 |
Ganglia, Spinal/cytology | 2 | 8.0 |
Solubility | 6 | 0.0 |
Nerve Regeneration/*physiology | 2 | 7.0 |
Drug Delivery Systems | 2 | 2.0 |
Mice, Neurologic Mutants | 4 | 3.0 |
Neurons/drug effects | 3 | 13.0 |
Hela Cells | 2 | 0.0 |
Neurotrophin 3 | 6 | 7.0 |
Cell Division/drug effects | 8 | 0.0 |
Choline O-Acetyltransferase/*metabolism | 2 | 1.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Embryo | 2 | 0.0 |
Neurites/drug effects/physiology | 3 | 20.0 |
Cytokines/*physiology | 3 | 1.0 |
Gene Expression Regulation | 3 | 0.0 |
Receptors, Cytokine/*physiology | 2 | 7.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Tyrosine 3-Monooxygenase/genetics | 2 | 4.0 |
Cell Death | 3 | 0.0 |
*Membrane Glycoproteins | 3 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Receptor, Ciliary Neurotrophic Factor | 20 | 22.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*physiology | 2 | 3.0 |
Receptors, Nerve Growth Factor/*physiology | 3 | 21.0 |
Tissue Distribution | 2 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Neuroprotective Agents/pharmacology | 3 | 8.0 |
Nerve Growth Factors/*genetics | 7 | 12.0 |
Hamsters | 4 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Signal Transduction/physiology | 3 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
DNA/chemistry/metabolism | 3 | 3.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Biological Markers | 2 | 0.0 |
Growth Inhibitors/*metabolism | 4 | 7.0 |
Lymphokines/*metabolism | 3 | 0.0 |
Peptides/*metabolism | 2 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Temperature | 2 | 0.0 |
Cytokines/*blood | 2 | 0.0 |
*Alleles | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Lymphokines/metabolism | 2 | 0.0 |
Cell Differentiation | 7 | 0.0 |
Nerve Growth Factors/physiology | 2 | 10.0 |
Nerve Tissue Proteins/physiology | 5 | 12.0 |
*Genetic Vectors | 2 | 0.0 |
Hela Cells/metabolism | 2 | 1.0 |
Drug Synergism | 7 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Cytokines/physiology | 2 | 1.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Interleukin-6/chemistry/*metabolism | 2 | 50.0 |
Receptors, Interleukin-6 | 8 | 9.0 |
Cloning, Molecular | 4 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Choline O-Acetyltransferase/metabolism | 6 | 4.0 |
Autoradiography | 2 | 0.0 |
Nerve Growth Factors/metabolism | 2 | 3.0 |
Choline O-Acetyltransferase/biosynthesis | 2 | 33.0 |
DNA Mutational Analysis | 2 | 0.0 |
Haptoglobins/biosynthesis | 2 | 33.0 |
Nerve Tissue Proteins/genetics/*metabolism/pharmacology | 2 | 33.0 |
Receptors, Cytokine/*metabolism | 3 | 3.0 |
Heterozygote | 2 | 0.0 |
Sciatic Nerve/*metabolism | 2 | 100.0 |
Peptides/pharmacology | 3 | 1.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Cell Count | 3 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Interleukin-6/*pharmacology | 4 | 1.0 |
Receptors, Interleukin/*metabolism | 2 | 6.0 |
Pregnancy | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Interleukin-11/pharmacology | 2 | 8.0 |
Liver Neoplasms | 2 | 0.0 |
Receptors, Nerve Growth Factor/physiology | 2 | 12.0 |
Brain-Derived Neurotrophic Factor | 9 | 10.0 |
In Vitro | 4 | 0.0 |
Motor Neurons/drug effects/*physiology | 2 | 66.0 |
*Chromosome Mapping | 2 | 0.0 |
Exons | 2 | 0.0 |
Introns | 2 | 0.0 |
Motor Neurons/*drug effects | 4 | 50.0 |
Growth Inhibitors/physiology | 2 | 8.0 |
Lymphokines/physiology | 2 | 2.0 |
DNA/genetics | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Nerve Tissue Proteins/*physiology | 4 | 6.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
*Signal Transduction | 5 | 0.0 |
Escherichia coli | 2 | 0.0 |
Nerve Tissue Proteins/*deficiency/genetics | 2 | 25.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Ganglia, Spinal/drug effects/physiology | 2 | 66.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Receptors, Growth Factor/physiology | 2 | 4.0 |
Motor Neurons/*pathology | 2 | 10.0 |
Astrocytes/physiology | 2 | 13.0 |
Electrophysiology | 2 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Molecular Probes/genetics | 2 | 2.0 |
Cross-Linking Reagents | 3 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Neurons/cytology/drug effects | 3 | 27.0 |
Iodine Radioisotopes | 3 | 0.0 |
Neuroblastoma/metabolism | 2 | 3.0 |
RNA, Messenger/analysis/*biosynthesis | 2 | 6.0 |
Neurons/cytology/*physiology | 3 | 9.0 |
Molecular Weight | 2 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Cell Survival/physiology | 3 | 1.0 |
Neurons/cytology/metabolism | 2 | 2.0 |
Nerve Degeneration/*drug effects | 2 | 25.0 |
*Antigens, CD | 4 | 0.0 |
Membrane Glycoproteins/*physiology | 3 | 1.0 |
Peptides/*pharmacology | 2 | 0.0 |
Peptides/physiology | 2 | 5.0 |
Brain/*metabolism | 2 | 0.0 |
Fetus | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Interleukin-6/physiology | 2 | 3.0 |
*Receptors, Cytokine | 3 | 2.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Brain/pathology | 2 | 0.0 |
Lentivirus/*genetics | 2 | 5.0 |
Molecular Structure | 2 | 0.0 |
Receptors, Cell Surface/drug effects/*metabolism | 2 | 4.0 |
Receptors, Nerve Growth Factor | 2 | 4.0 |
Organ Specificity | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
